文献速递胸部肿瘤

不可切除III期非小细胞肺癌患者放化疗后接受度伐利尤单抗治疗的特征与真实世界无进展生存:PACIFIC-R研究结果

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
PubMed 文献 · J Thorac Oncol · 2022-10-25

PACIFIC-R是一项国际回顾性研究,纳入11个国家1399例不可切除III期NSCLC患者,评估放化疗后度伐利尤单抗巩固治疗的真实世界有效性与安全性。中位随访23.5个月,中位真实世界无进展生存期为21.7个月,同步放化疗者(23.7个月)数值上长于序贯放化疗者(19.3个月)。

要点

  • 度伐利尤单抗巩固治疗中位真实世界无进展生存期为21.7个月(95%CI 19.1-24.5)。
  • 同步放化疗者中位rwPFS 23.7个月,数值上长于序贯放化疗者的19.3个月。
  • PD-L1表达≥1%者中位rwPFS 22.4个月,数值上长于PD-L1<1%者的15.6个月。

核心结论

  • 在不可切除III期NSCLC患者中,根治性放化疗后度伐利尤单抗巩固治疗在该大型真实世界队列中耐受性良好且有效。
  • 如预期,同步放化疗者及PD-L1表达较高者的真实世界无进展生存期更长。
  • 尽管如此,无论上述因素如何,均观察到有利的真实世界无进展生存结局。

研究设计与样本

  • PACIFIC-R(NCT03798535)是一项正在进行的国际回顾性研究。
  • 纳入2017年9月至2018年12月期间在早期准入项目中开始度伐利尤单抗(静脉给药,10 mg/kg,每2周一次)治疗的患者。
  • 主要终点为研究者评估的真实世界无进展生存期和总生存期,采用Kaplan-Meier法分析。
  • 截至2020年11月30日,全分析集包含来自11个国家的1399例患者,中位随访时间23.5个月。

主要发现

  • 患者接受度伐利尤单抗治疗的中位时间为11.0个月。
  • 中位真实世界无进展生存期为21.7个月(95%CI 19.1-24.5)。
  • 接受同步放化疗者中位rwPFS为23.7个月,序贯放化疗者为19.3个月。
  • PD-L1表达≥1%者中位rwPFS为22.4个月,PD-L1表达<1%者为15.6个月。
  • 16.5%的患者发生导致治疗中止的不良事件,9.5%的患者因肺炎或间质性肺病中止治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). The observational PACIFIC-R study assesses the real-world effectiveness of durvalumab in patients from an early access program. Here, we report treatment characteristics and a preplanned analysis of real-world progression-free survival (rwPFS). METHODS: PACIFIC-R (NCT03798535) is an ongoing, international, retrospective study of patients who started durvalumab (intravenously; 10 mg/kg every 2 wk) within an early access program between September 2017 and December 2018. The primary end points are investigator-assessed rwPFS and overall survival (analyzed by Kaplan-Meier method). RESULTS: As of November 30, 2020, the full analysis set comprised 1399 patients from 11 countries (median follow-up duration, 23.5 mo). Patients received durvalumab for a median of 11.0 months. Median rwPFS was 21.7 months (95% confidence interval: 19.1-24.5). RwPFS was numerically longer among patients who received concurrent versus sequential CRT (median, 23.7 versus 19.3 mo) and among patients with programmed cell death-ligand 1 expression greater than or equal to 1% versus less than 1% (22.4 versus 15.6 mo). Overall, 16.5% of the patients had adverse events leading to treatment discontinuation; 9.5% of all patients discontinued because of pneumonitis or interstitial lung disease. CONCLUSIONS: Consolidation durvalumab after definitive CRT was well tolerated and effective in this large, real-world cohort study of patients with unresectable, stage III NSCLC. As expected, rwPFS was longer among patients who received concurrent versus sequential CRT and patients with higher programmed cell death-ligand 1 expression. Nevertheless, favorable rwPFS outcomes were observed regardless of these factors.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Girard N, Bar J, Garrido P, et al. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2022. PMID: 36307040. doi:10.1016/j.jtho.2022.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。